Big Changes Coming to Big Pharma
The following video is part of our "Motley Fool Conversations" series, in which, Austin Smith, consumer goods editor and analyst, and David Williamson, health-care editor and analyst, discuss topics around the investing world.
In today's edition, they discuss how Pfizer continues to shake things up. A dividend increase is on the way, and the company is looking to spin off or sell the animal health and nutrition business and use the money to bolster its pipeline -- a pipeline that needs to absorb the loss of the worlds best selling drug Lipitor.
Editor's note: Since the filiming of this video, Pfizer has increased its dividend.
Looking for our prediction for 2012? Check out The Motley Fool's brand new report, "The Motley Fool's Top Stock for 2012." It highlights a company that is revolutionizing commerce in Latin America. You can get instant access to the name of this company by clicking here -- it's free. It won't be there forever, so check it out today.
At the time this article was published Austin Smith and David Williamson both own shares of Pfizer. The Motley Fool owns shares of Abbott Laboratories.Motley Fool newsletter serviceshave recommended buying shares of Pfizer and Abbott Laboratories. Try any of our Foolish newsletter servicesfree for 30 days. We Fools don't all hold the same opinions, but we all believe thatconsidering a diverse range of insightsmakes us better investors. The Motley Fool has adisclosure policy.
Copyright © 1995 - 2011 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.